both in combination with metformin and a sulfonylurea
INVOKANA® helped reduce A1C levels by a greater amount than Januvia®
INVOKANA® helped more people reach the ADA's recommended A1C goal of less than 7%
INVOKANA® helped contribute to weight loss in patients while Januvia® did not
The most common side effects of INVOKANA® include genital yeast infections, urinary tract infection, and changes in urination.
*Januvia® is a registered trademark of Merck Sharp & Dohme Corp.
INVOKANA® is available in 100 mg and 300 mg, the starting dose is 100 mg.
Over the course of one year, INVOKANA® 300 mg and Januvia® 100 mg were compared in a head-to-head clinical study where INVOKANA® achieved better results in several areas, including A1C reductions and weight loss.